Cipla, Eli Lilly Join Forces to Launch Tirzepatide in India as Yurpeak

Cipla and Eli Lilly India have announced an agreement to distribute a type 2 diabetes drug, tirzepatide, under the new brand name Yurpeak in India. This move aims to expand drug availability beyond cities, addressing the growing health concerns of diabetes and obesity in the country.

In a strategic alliance, Cipla and Eli Lilly and Company (India) unveiled plans to distribute and promote the type 2 diabetes drug tirzepatide in India, under the fresh brand name, Yurpeak.

This collaboration aims to enhance the accessibility of tirzepatide across India, particularly in areas beyond major cities, leveraging Cipla's expansive distribution network.

As India grapples with rising rates of type 2 diabetes and obesity, this partnership marks a significant step in providing wider access to innovative health solutions.